[1,4']Bipiperidinyl-1'-carboxylic acid 4-aminophenylester | 202745-11-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: [1,4']Bipiperidinyl-1'-carboxylic acid 4-aminophenylester
• 英文别名: (4-Aminophenyl) 4-piperidin-1-ylpiperidine-1-carboxylate
• CAS: 202745-11-7
• 化学式: C₁₇H₂₅N₃O₂
• 分子量: 303.404
• InChiKey: NGELOJAXXHSUDB-UHFFFAOYSA-N

物化性质

• 沸点：
  463.2±45.0 °C(Predicted)
• 密度：
  1.194±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  22
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.59
• 拓扑面积：
  58.8
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  [1,4']Bipiperidinyl-1'-carboxylic acid 4-aminophenylester 在 吡啶 、 三光气 、 六甲基二锡 、 三乙胺 、 N,N'-二环己基碳二亚胺 作用下， 以 二氯甲烷 、 苯 为溶剂， 反应 14.0h， 生成 伊立替康
  参考文献：
  名称：

  A General Synthetic Approach to the (20S)-Camptothecin Family of Antitumor Agents by a Regiocontrolled Cascade Radical Cyclization of Aryl Isonitriles

  摘要：

  A general and efficient synthesis of (20S)-camptothecin (1a) is reported. A key common intermediate containing the pyridone and lactone (DE) rings of camptothecin and most derivatives was constructed from 2-trimethylsilyl-6-methoxypyridine by a series of metalation reactions and a Heck cyclization to provide an achiral bicyclic enol ether. Sharpless asymmetric dihydroxylation followed by lactol oxidation and iododesilylation produced the key intermediate in 94% enantiomeric excess. Alkylation with propargyl bromide and a cascade radical reaction with phenyl isonitrile then produced 1a. About 20 other penta- and hexacyclic analogues of camptothecin with differing single or multiple substituents at C7, C9, C10, C11, and/or C12 were made by changing the propargylating agent and the isonitrile. Included among these are several drug candidates and the approved drugs topotecan and irinotecan. The synthesis of the prodrug irinotecan is direct one that does not pass through the active metabolite. The use of ortho-trimethylsilyl-substituted isonitriles allows the regioselective synthesis of camptothecin analogues in cases where isomeric mixtures are formed from the parent isonitriles. The synthesis of the derivatives relies on the broad scope and functional group tolerance of the key cascade radical reaction.

  DOI：

  10.1002/(sici)1521-3765(199801)4:1<67::aid-chem67>3.0.co;2-f
• 作为产物：
  描述：

  4-哌啶基哌啶 在 palladium on activated charcoal 氢气 、 三乙胺 作用下， 以 四氢呋喃 、 乙酸乙酯 为溶剂， 反应 14.0h， 生成 [1,4']Bipiperidinyl-1'-carboxylic acid 4-aminophenylester
  参考文献：
  名称：

  A General Synthetic Approach to the (20S)-Camptothecin Family of Antitumor Agents by a Regiocontrolled Cascade Radical Cyclization of Aryl Isonitriles

  摘要：

  A general and efficient synthesis of (20S)-camptothecin (1a) is reported. A key common intermediate containing the pyridone and lactone (DE) rings of camptothecin and most derivatives was constructed from 2-trimethylsilyl-6-methoxypyridine by a series of metalation reactions and a Heck cyclization to provide an achiral bicyclic enol ether. Sharpless asymmetric dihydroxylation followed by lactol oxidation and iododesilylation produced the key intermediate in 94% enantiomeric excess. Alkylation with propargyl bromide and a cascade radical reaction with phenyl isonitrile then produced 1a. About 20 other penta- and hexacyclic analogues of camptothecin with differing single or multiple substituents at C7, C9, C10, C11, and/or C12 were made by changing the propargylating agent and the isonitrile. Included among these are several drug candidates and the approved drugs topotecan and irinotecan. The synthesis of the prodrug irinotecan is direct one that does not pass through the active metabolite. The use of ortho-trimethylsilyl-substituted isonitriles allows the regioselective synthesis of camptothecin analogues in cases where isomeric mixtures are formed from the parent isonitriles. The synthesis of the derivatives relies on the broad scope and functional group tolerance of the key cascade radical reaction.

  DOI：

  10.1002/(sici)1521-3765(199801)4:1<67::aid-chem67>3.0.co;2-f

文献信息

• Camptothecin analogs and methods of preparation thereof
  申请人：Curran P. Dennis

  公开号：US20070259905A1

  公开（公告）日：2007-11-08

  The present invention provides generally a compound having the following general formula (1): wherein R 1 and R 2 are independently the same or different and are hydrogen, an alkyl group, an alkenyl group, a benzyl group, an alkynyl group, an alkoxyl group, an aryloxy group, an acyloxy group, a carbonyloxy group, a carbamoyloxy group, a halogen, a hydroxyl group, a nitro group, a cyano group, an azido group, a formyl group, a hydrazino group, an acyl group, an amino group, —SR c , wherein, R c is hydrogen, an acyl group, an alkyl group, or an aryl group, or R 1 and R 2 together form a group of the formula —O(CH 2 ) n O— wherein n represents the integer 1 or 2; R 3 is H, F, a halogen atom, a nitro group, an amino group, a hydroxyl group, or a cyano group; or R 2 and R 3 together form a group of the formula —O(CH 2 ) n O— wherein n represents the integer 1 or 2; R 4 is H, F, a C 1-3 alkyl group, a C 2-3 alkenyl group, a C 2-3 alkynyl group, or a C 1-3 alkoxyl group; R 5 is a C 1-10 alkyl group, or a propargyl group; and R 6 , R 7 and R 8 are independently a C 1-10 alkyl group, a C 2-10 alkenyl group, a C 2-10 alkynyl group, an aryl group or a —(CH 2 ) N R 9 group, wherein N is an integer within the range of 1 through 10 and R 9 is a hydroxyl group, alkoxy group, an amino group, an alkylamino group, a dialkylamino group, a halogen atom, a cyano group or a nitro group; and pharmaceutically acceptable salts thereof.

  本发明提供了一种化合物，其具有以下通用式（1）：其中R1和R2独立且相同或不同，可以是氢、烷基、烯基、苯甲基、炔基、烷氧基、芳氧基、酰氧基、羰基氧基、氨基甲酰氧基、卤素、羟基、硝基、氰基、叠氮基、甲酰基、肼基、酰基、氨基、-SRc，其中，Rc为氢、酰基、烷基或芳基；或者R1和R2共同形成以下式的基团—O（CH2）nO—其中n表示整数1或2；R3为H、F、卤素原子、硝基、氨基、羟基或氰基；或者R2和R3共同形成以下式的基团—O（ ）nO—其中n表示整数1或2；R4为H、F、C1-3烷基、C2-3烯基、C2-3炔基或C1-3烷氧基；R5为C1-10烷基或丙炔基；R6、R7和R8独立地为C1-10烷基、C2-10烯基、C2-10炔基、芳基或-（ ）NR9基团，其中N在1至10范围内，R9为羟基、烷氧基、氨基、烷基氨基、二烷基氨基、卤素原子、氰基或硝基；以及其药学上可接受的盐。
• US6150343A
  申请人：——

  公开号：US6150343A

  公开（公告）日：2000-11-21
• US7514418B2
  申请人：——

  公开号：US7514418B2

  公开（公告）日：2009-04-07